To validate this, we examined the Hippo signaling in DSF-treated GES-1 and HGC-27 cells and found that DSF dose-dependently promoted the phosphorylation of LATS1, MOB1, and YAP in HGC27 cells but not GES-1 cells, results indicative of selectively reactivating Hippo signaling in cancer (Fig. 3D). The gene discussed is LATS1; the disease is cancer.